Skip to main
  1. Stocks
  2. Electra Therapeutics Inc
  3. Forecast
ETRA

ETRA Stock Forecast & Price Target

ETRA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Electra Therapeutics is compelling because its first-in-class SIRP-targeted platform has already shown human proof-of-concept, with ipsoprubart delivering 100% 8-week overall survival and 100% overall response in 12 frontline mHLH patients, including 10 partial responses and two modified complete responses. The company is addressing a severe, underserved market where U.S. diagnosed incidence reached about 12,600 in 2025 and could approach nearly 17,500 in 2028, supporting premium orphan pricing and meaningful commercial upside. Its outlook is further strengthened by Breakthrough Therapy and PRIME designations, a registrational program underway, a cash position of $97.7 million as of June 30, 2026, and an additional platform asset, ELA822, that broadens the pipeline beyond sHLH.

Bears say

Electra Therapeutics is a late clinical-stage biopharmaceutical company with no approved products and no projected revenue in either 2026 or 2027, leaving valuation dependent entirely on uncertain clinical progress rather than existing cash generation. The company faces substantial near-term cash burn, with projected R&D of $86.5 million in 2026 and $120 million in 2027, operating losses of $108.5 million and $160 million, and free cash outflows of about $105.4 million and $154.8 million, respectively. Its lead asset, ipsoprubart, relies on a single-arm SURPASS design and small uncontrolled datasets, while ELA822 is still early-stage, so clinical, regulatory, reimbursement, and execution risks could delay any U.S. launch before 2030 and force additional financing.

ETRA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Electra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

ETRA Analyst Forecast & Price Prediction

Get the latest ETRA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ETRA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Electra Therapeutics Inc (ETRA) Forecast

Analysts have given ETRA a Buy based on their latest research and market trends.

According to 4 analysts, ETRA has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Electra Therapeutics Inc (ETRA)


ETRA Analyst Forecast & Price Prediction

Get the latest ETRA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ETRA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ETRA stock data and trends